“…HIV-PIs inhibit the growth of numerous types of tumor cell lines, including multiple myeloma, SW872 liposarcoma, T24 bladder carcinoma, A549 lung carcinoma, U373 glioblastoma, Jurkat leukemia cells, DU-145 and PC-3 prostate cancer cells, NB4 and HL-60 human myelocytic leukemia cells, and Kaposi's sarcoma (6,7,9,12,14). These drugs are capable of decreasing the incidence of Kaposi's sarcoma and promoting its regression, and of amplifying the therapeutic efficacy of radiotherapy and chemotherapy of head, neck, bladder, and prostate cancers (7,8,10,11,13,14). However, long-term administration of HIV-PIs results in serious adverse side effects, including hyperbilirubinemia, hyperlipidemia or hypolipidemia, insulin resistance, and diabetes, among others (2).…”